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Advanced oxidation protein products (AOPP) are reportedly elevated in the plasma of patients with a number of diseases, including
diabetes mellitus, that involve oxidative stress. However, the accurate measurement of AOPP in human plasma is hampered by
the formation of a precipitate following the addition of potassium iodide and glacial acetic acid according to the published assay
procedure. Here we describe a modification of the AOPP assay which eliminates interference by precipitation and provides a
robust, reliable, and reproducible protocol for the measurement of iodide oxidising capacity in plasma samples (intra-assay CV
1.7–5.3%, interassay CV 5.3–10.5%). The improved method revealed a significant association of AOPP levels with age (𝑝 < 0.05)
and hypertension (𝑝 = 0.01) in EDTA-anticoagulated plasma samples from 52 patients with diabetes and 38 nondiabetic control
subjects, suggesting a possible link between plasma oxidising capacity and endothelial and/or vascular dysfunction. There was no
significant difference between AOPP concentrations in diabetic (74.8 ± 7.2 𝜇M chloramine T equivalents) and nondiabetic (75.5 ±
7.0𝜇M chloramine T equivalents) individuals.
1. Introduction
The availability of plasma oxidative damage assays which are
sensitive and robust is a limiting factor in high-throughput
studies of human disease and ageing [1]. The advanced oxi-
dation protein products (AOPP) assay is a widely published
method to determine plasma oxidative stress, based on a
spectrophotometric assay in a 96-well microplate format [2].
AOPP have been analysed in numerous diseases and are
widely regarded as an easily measurable marker of oxidative
stress [3–6].
Oxidative stress is a well-established feature of diabetes
mellitus and is believed to play an important role in the
development of diabetes-related complications [7]. Some
studies have found that AOPP are moderately elevated in
adult patients with Type 1 diabetes and more markedly
elevated in those with Type 2 diabetes [8, 9], although others
have suggested that AOPP are only significantly increased in
Type 2 diabetes [10]. They have been reported to be elevated
in Type 2 diabetes [11], and the concentration correlated
with insulin resistance [12] or the presence and/or severity
of diabetic complications [13, 14], such as retinopathy [15,
16] or nephropathy [17]. In juveniles and adolescents with
Type 1 diabetes, AOPP were found to accumulate over time
and were significantly associated with disease duration [18].
Others suggest that whilst AOPP concentrations are elevated
in children with Type 1 diabetes, there is no association with
disease duration [19].
We wished to adopt the AOPP assay for our own studies
of diabetic patients and control subjects, examining the
relationship between oxidative stress and risk factors such as
BMI, waist : hip ratio, and blood pressure. However, we report
here that the AOPP assay was prone to sample precipitation
and consequent poor reproducibility, and we describe a novel
modification of the method which measures the total iodide
ion (I−) oxidising capacity of plasma (hereafter referred to as
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Table 1: Demographic characteristics of the study cohort.
Controls T2DM T1/unclassified DM Total
n 38 49 3 90
Age (years ± S.D.) 57.8 ± 15.8 64.0 ± 11.0 32.3 ± 12.7 60.3 ± 14.6
Gender (male/female) 13/25 32/17 1/2 46/44
Smoking status (present/past/never) 4/11/23 3/27/19 0/1/2 7/39/44
Hypertension (absent/present) 26/12 23/26 3/0 52/38
BMI (mean ± S.D.) 27.2 ± 5.4 29.7 ± 5.3 25.2 ± 0.28 28.7 ± 5.4
Waist : hip (mean ± S.D.) 0.87 ± 0.10 0.96 ± 0.09 0.81 ± 0.11 0.92 ± 0.10
AOPPTIOC). The AOPPTIOC assay eliminates interference by
sample precipitation and provides greater reproducibility of
measurements within samples and a more accurate determi-
nation of the ability of a plasma sample to oxidise I− ions.
Application of this modified assay to plasma samples
from human diabetic patients and nondiabetic control sub-
jects demonstrated an increase in AOPPTIOC with age in
both diabetics and nondiabetics and a significant association
with the presence of hypertension, although there was no
difference in I− oxidising capacity between the two groups.
2. Materials and Methods
2.1. Materials. KI, chloramine T hydrate, and PBS were all
purchased from Sigma-Aldrich (Gillingham, UK). Glacial
acetic acid was from Fisher Scientific (Loughborough, UK)
and clear 96-well NUNC Maxisorp microplates were from
Greiner Bio One (Stonehouse, UK).
2.2. Plasma Samples. Plasma samples from diabetic patients
or nondiabetic controls were collectedwith informed consent
by the NIHR Clinical Research Facility at Peninsula Medical
School and analysed for their ability to oxidise I− to I
3
−. This
study had ethical approval from the North and East Devon
Research Ethics Committee and was conducted according to
the Declaration of Helsinki. A full medical history (includ-
ing past medical history of myocardial infarction, periph-
eral vascular disease, hypertension, retinopathy, neuropathy,
nephropathy, and cancer) plus physiological data (BMI, waist
and hip measurements, and blood pressure) was taken from
all participants at the time of venepuncture (Table 1). Routine
clinical chemistry measures included triglycerides, HbA1c,
and albumin. The mean age of the Type 2 diabetics was
64.0 ± 11.0 (mean ± 1 S.D.) years (𝑛 = 49), of the Type
1 or unclassified diabetics 32.3 ± 12.7 years (𝑛 = 3),
and of the nondiabetic control subjects 57.8 ± 15.8 years
(𝑛 = 38). Peripheral blood was collected into EDTA-coated
tubes and centrifuged (3000 g, 10min). Plasma was removed
and dispensed into 100 𝜇L aliquots before storage at −80∘C.
Samples were thawed at room temperature before analysis,
and repeated freeze-thaw cycles were avoided.
2.3. Previously Published AOPP Assay. For measurement of
AOPP, plasma samples were diluted to 10% in PBS and 200 𝜇L
applied in triplicate to a 96-well microplate. Standards of
chloramine T (200𝜇L; 0–100 𝜇M) were added to the plate.
KI (1.16M, 10 𝜇L) was added to all wells, followed 2min later
by bolus addition of 20𝜇L glacial acetic acid. The optical
density was then read immediately at 340 nm (OD
340
) using a
Fluostar Optima plate reader (BMG Labtech Ltd., Aylesbury,
UK).
2.4. AOPP
𝑇𝐼𝑂𝐶
Assay. Measurement of AOPPTIOC by our
protocol was carried out as follows. Plasma samples were
diluted to 10% in PBS and 300 𝜇L applied in triplicate to a
96-well microplate. Standards of chloramine T (300 𝜇L; 0–
100 𝜇M) were added to the plate and a sample blank was
prepared by adding 300 𝜇L PBS to the microplate. KI (1.16M,
15 𝜇L) was added to all wells, followed 2min later by bolus
addition of 30 𝜇L glacial acetic acid. The microplate was
centrifuged (5800 g, 5min) to pellet precipitated protein, and
230 𝜇L of supernatant was transferred to a clean microplate.
The OD
340
of the supernatant was read 10min after the
addition of glacial acetic acid. The optical density at 595 nm
(OD
595
), at which wavelength I
3
− does not absorb [20], was
also read as a “nonreaction” measure of sample turbidity and
light scattering. The optical density of the sample blank was
subtracted from all wells before data analysis.
2.5. Validation Studies. Three different dilutions (5%, 10%,
and 20%) of three plasma samples selected at random were
analysed for AOPPTIOC, followed by multiplication by the
dilution factor, to determine whether the same value of
AOPPTIOC is obtained whatever the sample dilution.
Coefficients of variation were calculated between tripli-
cate optical density measurements of a given sample (inter-
replicate CV), between AOPPTIOC values calculated from
numerous sets of triplicate measurements of the same sample
on the same plate using the same standard curve (intra-
assay CV), and between AOPPTIOC values calculated from
numerous sets of triplicate measurements of the same sample
on different microplates using different standard curves
(interassay CV).
2.6. Other Statistical Analyses. Statistical analyses were car-
ried out using GraphPad Prism 5 statistical software package.
Unpaired Student’s 𝑡-test was used to evaluate differences
in AOPPTIOC values involving two sets of categorical data
(diabetics versus nondiabetic controls; hypertensive versus
nonhypertensive individuals; gender) and ANOVA was used
where there were three or more sets of categorical data
(smoking status). Linear regression analyses, using Pearson’s
rank correlation coefficients (𝑟), were performed to assess
associations of AOPPTIOC values with continuous variables
Oxidative Medicine and Cellular Longevity 3
0.0
0.4
0.8
1.2
Sample 1 2 3 4
14.4 29.7 40.6 16.5
O
D
 at
3
4
0
nm
Replicate %
CV
(a)
0.0
0.1
0.2
0.3
0.4
0.5
Sample 1 2 3 4
2.4 3.6 7.1 6.5
O
D
 at
5
9
5
nm
Replicate %
CV
(b)
0.0
0.4
0.8
1.2
Sample 1 2 3 4
13.9 26.6 32.9 19.9
O
D
 at
3
4
0
nm
Replicate %
CV
(c)
0.0
0.1
0.2
0.3
0.4
0.5
Sample 1 2 3 4
6.2 1.3 6.5 9.4
O
D
 at
5
9
5
 n
m
Replicate %
CV
(d)
Figure 1: Improved reproducibility of the modified AOPPTIOC assay after centrifugation (5800 g, 5min) of the microplate and transfer of
supernatant. Four random plasma samples were taken and optical density was measured at a wavelength of 340 nm following (a) the original
protocol and (c) our modified protocol. Optical density was also measured at 595 nm in (b) the original protocol and (d) our modified
protocol in order to examine sample turbidity. Bars represent triplicate optical density values obtained, with each type of shading representing
a different plasma sample. Numbers under the appropriate bars represent the % coefficient of variation (% CV) of the triplicate measurements
for that particular sample.
(age; diabetes disease duration; HbA1c, BMI; waist : hip ratio,
serumalbumin, and triglyceride concentration). In all cases, a
𝑝 value <0.05 was taken to represent a statistically significant
difference.
3. Results
Plasma was initially analysed using a previously published
AOPP method [8–10, 12, 17]. Of the 77 plasma samples
assessed from both diabetic patients and nondiabetic control
subjects, only 27 produced an interreplicate CV of less than
20%, and only six of these were under 10% (see Supplemen-
tary Material 1 available online at http://dx.doi.org/10.1155/
2015/496271).Themedian interreplicate CV of the 77 samples
was 26.2% (interquartile range 16.7–44.0%). Consequently,
high variability was seen when one sample was analysed on
five separate occasions (Supplementary Material 2).
Precipitation was seen in plasma samples from both
diabetics (31 of 39 samples; 79.5%) and control subjects (19
of 38 samples; 50.0%). The highest % CVs were seen in the
samples that had lower blank optical density values (𝑟 =
−0.310, 𝑝 < 0.05), so the variability was not related to high
inherent sample optical density; indeed the reverse was true.
The individual microplate wells that gave a high apparent
optical density reading corresponded to wells in which a pre-
cipitate could be seen. Furthermore, the change in OD
595
on
addition of I− and acetic acid mirrored the change in OD
340
(representative data from four samples is shown in Figure 1,
panels (a) and (c)), demonstrating that sample turbidity had
altered and variability between replicate values was not alone
due to differences in the extent of I− oxidation. Therefore
the assay was modified in order to allow the removal of the
precipitate from the samples before the optical density was
read, to generate amethodwhichwenamed “AOPPTIOC.”This
involved increasing all volumes in the assay by 50%, followed
by centrifugation of the microplate (5800 g, 5min) and the
subsequent transfer of supernatants (230𝜇L, equal to the final
volume per well in the original method) to a fresh microplate
before optical densitymeasurementswere taken.The increase
in sample and reagent volumes by 50% facilitated the removal
of the supernatant after microplate centrifugation, leaving
behind the pelleted precipitate, which was discarded.
Four plasma samples were selected to test the repro-
ducibility of replicates using this modified method.The same
samples were also analysed by the original method for com-
parison. Using the original method, interreplicate CVs were
all over 10% (range 14.4–40.6%; Figure 1(a)) and nonreaction
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Table 2: Evaluation of the linearity of AOPPTIOC measurements.
Plasma sample number Dilution (%) Mean blank Mean test AOPPTIOC (𝜇M chloramine T equivalents)
OD340 OD340 AOPPTIOC1
a x dilution AOPPTIOC2
b x dilution
1
5 0.068 0.032 4.37 87.4 2.09 41.8
10 0.123 0.131 17.17 171.7 4.14 41.4
20 0.209 0.602 78.38 391.9 8.85 44.3
2
5 0.075 0.040 5.35 107.1 2.31 46.3
10 0.130 0.161 21.07 210.7 4.59 45.9
20 0.224 0.641 83.46 417.3 9.14 45.7
3
5 0.123 0.058 7.76 155.2 2.79 55.7
10 0.220 0.202 26.48 264.8 5.15 51.5
20 0.404 0.800 104.13 520.6 10.20 51.0
OD340: optical density at 340 nm.
aAOPPTIOC1: AOPPTIOC concentration calculated fromoriginal optical density values using the standard curve.
bAOPPTIOC2:
square root of AOPPTIOC1.
measurements (OD
595
) were similarly variable (range 13.9–
32.9%; Figure 1(c)). In contrast, using our modified protocol,
optical density measurements were lower than those seen
with the original method and more consistent, with inter-
replicate CVs all under 10% (range 2.4–7.1%; Figure 1(b)).
The improved reproducibility of these measurements was
mirrored by the low variability in optical density values
at 595 nm (range 1.3–9.4%; Figure 1(d)), indicating that the
precipitate had successfully been removed.
Three plasma samples were selected and diluted to 5%,
10%, and 20% in PBS. AOPPTIOC was then measured using
our method and the values obtained multiplied by the
appropriate dilution factor for comparison purposes (Table 2,
column 6). Although the optical density of the standards was
linear across the range of concentrations tested as previously
described [2], and blankODvalues of plasma samples (before
addition of I− and acetic acid; Table 2, column 3) also approx-
imated the expected linear relationship, this was not the case
for plasma samples following addition of iodide and acid.
As the amount of plasma present in the well doubled (20%
versus 10% plasma and 10% versus 5% plasma), the associated
AOPPTIOC increased fourfold. Similarly, a fourfold increase
in plasma concentration (20% versus 5% plasma) produced
an AOPPTIOC value that was sixteen times higher. This
could be converted to a linear relationship by a square root
transformation of AOPPTIOC calculated from the standard
curve as chloramine T equivalents. Doing this, and subse-
quently multiplying by the dilution factor, produced consis-
tent AOPPTIOC values. The mean ± S.D. of the AOPPTIOC
concentration determined from the three different dilutions
was 42.5 ± 1.6 𝜇M in one plasma sample, 46.0 ± 0.3 𝜇M in
another, and 53.6 ± 3.0 𝜇M in the third (Table 2, column 8).
This relationship between plasma dilution and OD
340
does not merely represent differences in the degree of light
scattering due to protein precipitation. Actual fold-change in
OD at a nonspecific wavelength (OD
595
), at which I
3
− does
not absorb light, did not show the same relationship between
OD and plasma dilution (data not shown). Thus, association
of OD with the square of the plasma sample concentration
was specific for the 340 nm wavelength at which I
3
− absorbs
light.
It was noted that, despite the centrifugation step, there
remained a difference in OD
595
between samples (typically
ranging from 0.05 to 0.15 OD; data not shown) and within
the same sample analysed on different days.These differences
probably reflect inherent differences in sample composition
that are present even before the initiation of protein pre-
cipitation and varying degrees of precipitate formation and
removal from one sample on different days, respectively.
Such differences may interfere with the assay and make
comparisons between samples problematic.Therefore, OD
340
was additionally normalised to an OD
595
of 0.1, in order to
account for these differences, and the resulting normalised
OD
340
value (nOD
340
)was analysed by linear regression using
the standard curve.
Taking the above two points into consideration, we
derived the following algorithm for the determination of
AOPPTIOC.
Step 1. Calculation of normalised OD
340
(nOD
340
) is as
follows:
nOD
340
= [
(OD
340
)
(OD
595
× 10)
] . (1)
Step 2. Calculation of 𝑥 from nOD
340
using linear regression
is as follows:
𝑥 =
(nOD
340
− 𝑐)
𝑚
, (2)
where𝑦 = 𝑚𝑥+𝑐 describes the equation of the standard curve
and 𝑦 = nOD
340
.
Step 3. Square root transformation of 𝑥 (𝑥srt) is as follows:
𝑥srt = (𝑥
1/2
) . (3)
Step 4. Multiplication by dilution factor is as follows:
AOPPTIOC = 𝑥srt × 10
(𝜇M chloramine T equivalents) .
(4)
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Table 3: Intra-assay and interassay coefficients of variation.
AOPPTIOC values (𝜇M chloramine T equivalents)
Intra-assay Sample A (𝑛 = 6) Sample B (𝑛 = 6) Sample C (𝑛 = 6) Sample D (𝑛 = 6) Sample E (𝑛 = 6)
Mean 77.6 79.7 70.2 56.7 57.6
S.D. 1.3 2.7 3.4 2.0 3.1
CV (%) 1.7 3.4 4.8 3.5 5.3
Interassay Sample F (𝑛 = 6) Sample G (𝑛 = 6) Sample H (𝑛 = 8) Sample I (𝑛 = 7) Sample J (𝑛 = 8)
Mean 74.6 68.9 65.3 72.5 73.2
S.D. 5.2 3.6 6.8 6.7 6.7
CV (%) 7.0 5.3 10.5 9.2 9.2
The intra-assay and interassay reproducibility of the assay
were assessed by measuring AOPPTIOC as described above in
several plasma samples. AOPPTIOC was measured six times
in triplicate on the same plate in five plasma samples selected
at random (Samples A–E). Table 3 shows that the intra-assay
CV in all five sampleswas under 6% (1.7–5.3%). InterassayCV
determinations were carried out using five plasma samples,
each of which wasmeasured at least six times over a period of
14 months (Samples F and G) or four months (Samples H–J).
Interassay CVs for the five samples ranged from 5.3 to 10.5%,
as shown in Table 3.
Themodified assaywas then applied to 90 plasma samples
from individuals with diabetes or control subjects (50 Type
2 diabetics, 3 subjects with unclassified diabetes, and 37
nondiabetic controls). It was found that AOPPTIOC values
were not significantly different between Type 2 diabetic and
nondiabetic individuals (𝑝 = 0.665 by unpaired Student’s 𝑡-
test).Mean (± 1 S.D.)AOPPTIOC in diabeticswas 74.8± 7.2𝜇M
chloramine T equivalents and in controls was 75.5 ± 7.0𝜇M
chloramine T equivalents. It was found that AOPPTIOC values
associated significantly with age in both nondiabetic (𝑟 =
0.392, 𝑝 < 0.05) and Type 2 diabetic (𝑟 = 0.489, 𝑝 < 0.05)
subjects, as assessed by Pearson’s rank correlation (Figure 2),
although AOPPTIOC did not correlate with disease duration
in 46 Type 2 diabetes patients for whom this information
was available (𝑟 = −0.024; 𝑝 > 0.05). AOPPTIOC also
significantly associated with age in the combined dataset
of 90 subjects, including the three subjects with Type 1 or
unclassified diabetes (𝑟 = 0.393, 𝑝 < 0.05).
Data from all 90 subjects was analysed in relation to other
morbidities that may influence AOPPTIOC values, in partic-
ular those that increase in prevalence with age. Using this
approach, only hypertension (38 hypertensive subjects and 52
nonhypertensive subjects) was present in sufficient numbers
of subjects to allow valid analyses to be undertaken. It was
found that AOPPTIOC associates with hypertension (𝑝 = 0.01
by two-tailed unpaired Student’s 𝑡-test), regardless of whether
or not the subjects had diabetes (Figure 3). Although the
maximum values were similar in nonhypertensive (88.9 𝜇M
chloramine T equivalents) and hypertensive (87.1 𝜇M chlo-
ramine T equivalents) subjects, the data in hypertensive
individuals was clustered around the higher end of the range
of values such that the minimum value in hypertensives was
67.1 𝜇M chloramine T equivalents compared with 56.6𝜇M
chloramine T equivalents in nonhypertensives. The mean
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Figure 2: Association of AOPPTIOC with age in nondiabetic and
diabetic subjects. AOPPTIOC was measured in 37 subjects without
diabetes and 50 patients with Type 2 diabetes and linear regression
analyses (Pearson’s rank correlation) of AOPPTIOC versus age were
performed. Both diabetic (𝑟 = 0.485) and nondiabetic (𝑟 = 0.388)
individuals showed a significant (𝑝 < 0.05) increase in AOPPTIOC
with age. Open circles represent data from nondiabetic individuals
and dashed line shows the linear trendline through the data. Grey
squares represent subjects with Type 2 diabetes and the linear
trendline is shown by the solid line.
age of the hypertensive individuals (66.8 ± 1.3 years) was
significantly higher (𝑝 < 0.001, two-tailed unpaired Student’s
𝑡-test) than the nonhypertensive individuals (55.6 ± 2.3
years).
No association was seen between AOPPTIOC concentra-
tion and BMI (𝑛 = 90, 𝑟 = 0.085; 𝑝 > 0.05) as assessed
by Pearson’s rank correlation analysis. A trend towards an
association with waist:hip ratio was seen, but this did not
reach statistical significance in this study (𝑛 = 87, 𝑟 = 0.195;
𝑝 > 0.05). Furthermore, there was no correlation between
AOPPTIOC and HbA1c (𝑛 = 36, 𝑟 = −0.138; 𝑝 > 0.05), serum
albumin (𝑛 = 29; 𝑟 = −0.084; 𝑝 > 0.05), or triglycerides
(𝑛 = 27, 𝑟 = −0.187; 𝑝 > 0.05).
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Figure 3: Elevated AOPPTIOC in subjects with hypertension. Sub-
jects were divided into 52 normotensive individuals and 38 subjects
diagnosed with hypertension and logistic analysis of their associated
plasmaAOPPTIOC concentrations performed by two-tailed Student’s
𝑡-test. A significant (𝑝 < 0.05) difference in AOPPTIOC was found
between the two groups.
Smoking status did not influence the values obtained,
as mean ± 1 S.D. AOPPTIOC was 75.5 ± 6.5 𝜇M chloramine
T equivalents in nonsmokers (𝑛 = 44), 74.6 ± 7.6 𝜇M
chloramine T equivalents in past smokers (𝑛 = 39), and 74.4±
7.5 𝜇M chloramine T equivalents in present smokers (𝑛 = 7)
(𝑝 > 0.05 by unpaired one-way ANOVA). Additionally, there
was no difference betweenmales (74.7 ± 7.3 𝜇Mchloramine T
equivalents, 𝑛 = 46) and females (75.5± 6.7 𝜇Mchloramine T
equivalents, 𝑛 = 44) as assessed by unpaired Student’s 𝑡-test.
A subset of 23 samples was reanalysed between nine
and 22 months after initial analysis in order to determine
the reproducibility of incurred samples on repeat analysis.
Twenty-two of these samples (95.7%) were found to give
AOPP concentrations within 20% of the original values, and
52.2% of samples were within 10%.
4. Discussion
In the present study, we set out to study oxidative stress in
patients with diabetes. We used the AOPP assay, in which the
capacity of plasma samples to oxidise I− to I
3
− is analysed [16,
17, 21–25]. Chloramine T is used as a standard, although a
number of plasma constituents contribute to the oxidation of
I− to I
3
−, including hydroperoxides [26], peroxidases [27, 28],
and dehydromethionine [29]. The chemical equation of the
reaction between chloramines and I− is
RNHCl + 3I− (colourless) +H+
←→ I
3
−
(yellow-brown) + RNH
2
+ Cl−
(5)
The I
3
− product has a 𝜆max at 353 nm [20] and can there-
fore be measured spectrophotometrically. Recent studies [21,
30] have suggested that oxidised fibrinogen is the oxidiser of
I− in this assay, where oxidised fibrinogenmay, in turn, result
from the activity of myeloperoxidase during inflammation
[31]. However, this method showed very large discrepancies
between replicate measurements for plasma samples, due to
previously unreported interference by a protein precipitate,
which varied between wells and between samples. Therefore,
in its existing form, the AOPP assay was unsuitable for the
reliable determination of AOPP.
We set out to modify the protocol to generate a method
that we termedAOPPTIOC such that the interreplicate CVwas
reduced and the intra- and interassay CVs were minimized
[32]. It was necessary to remove the precipitate formed on
addition of I− and acetic acid by microplate centrifugation
to pellet the precipitate, followed by transfer of supernatant
to a new microplate before measurement. The OD
340
of trip-
licate measurements then became acceptably reproducible.
There was no correlation between AOPPTIOC concentration
and serum albumin concentration, demonstrating that the
modified method is independent of protein concentration
and does notmerely reflect increased precipitation in samples
with higher protein content.
Reproducibility studies showed the modified assay to be
within acceptable limits. Interassay variation was not higher
in those samples in which repeat analyses were performed
over a longer period of time (14 months) compared to a short
period of time (4 months), suggesting that AOPP are stable
on storage at −80∘C for at least one year. Incurred sample
reanalysis (ISR) surpassed the recommended standards for
analytical methods. The Crystal City III guidelines issued by
the FDA in 2007 recommended that two-thirds of samples
must fall within 20% of the original value on ISR in order for
an analytical assay to be deemed valid [33].
We wished to establish if the modified AOPPTIOC proto-
col also demonstrated increased values in diabetic patients.
However, no such differences existed between the popula-
tions of diabetics and nondiabetics, and there was no associa-
tion with poor glycaemic control, as measured by glycated
haemoglobin (HbA1c).
However, AOPPTIOC was significantly associated with the
presence of hypertension, a common comorbidity of diabetes.
A previous study reported that AOPP concentrations cor-
relate with the degree of arterial stiffness in humans [24],
which leads to an elevation of systolic blood pressure and
risk of clinical hypertension [34]. Furthermore, it has recently
been reported that AOPP is associated with endothelial
dysfunction [35]which predisposes to hypertension. Both the
above studies involved addition of KI to samples as well as to
standards.Thus, our findings support the conclusions of these
previous studies which used a method that is closely related
to our modified version.
Our inability to reproduce previous studies examining
AOPP concentrations in diabetics and nondiabetic controls
might be explained by a higher incidence of hypertension
in the diabetic cohort of other studies, as hypertension is
a common comorbidity of diabetes. Hypertension (or sub-
clinical elevated blood pressure) rather than diabetes per se
may have been the factor linked to increased iodide oxidation
in the diabetic group. For example, in one study [17], mean
blood pressure (systolic ± 1 S.D./diastolic ± 1 S.D.) in healthy
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controls was 118 ± 29/72 ± 19mm Hg and in diabetics was
141 ± 14/76 ± 10mmHg. Additionally, Kalousova´ et al. [8]
reported that AOPP in patients with Type 2 diabetes (mean
blood pressure 139 ± 9/86 ± 6mmHg) was more highly
elevated from healthy control values (𝑝 < 0.001) than in
patients with Type 1 diabetes (mean blood pressure 123 ±
13/80 ± 7mmHg; 𝑝 < 0.05 versus healthy controls). Thus,
the patient group with a more strongly elevated mean blood
pressure was also the group which showed a higher elevation
of mean AOPP concentration.
Alternatively, interference in the AOPP assay by elevated
triglycerides [36] due to hyperlipidaemia or differences in
fasting status between sample groups may account in part
for the previous observations. Triglycerides are carried in the
blood in the form of chylomicrons, which scatter light [37],
but our modification of the protocol accounts for differences
in light scattering by normalising for the optical density of
the sample at 595 nm. In one previously published study,
the mean triglyceride concentration in healthy controls
was 102.7 ± 48.5mg/dL compared to 170.0 ± 71.3mg/dL
in diabetics [17]. Another study reported that AOPP was
higher in Type 2 diabetes (2.1 ± 1.0mM triglycerides) than
Type 1 diabetes (1.2 ± 0.5mM) [8]. In a further study, AOPP
were reported to be elevated in diabetes (0.84 ± 0.07mM
triglycerides), particularly in the presence of complications
(1.17 ± 0.14mM) compared to controls (0.63 ± 0.04mM) [38].
In our study, no association was found between triglyceride
concentration and AOPPTIOC concentration, suggesting that
our modification of the assay is not subject to interference
by triglycerides as is the case for other versions of the assay.
Similarly, other plasma components, such as NADH and
NADPH, absorb light at 340 nm [39] and may interfere with
an assay which only measures the optical density of a plasma
sample at this wavelength. However, no association was seen
between AOPPTIOC concentration and blank OD340 in all
subjects assessed during this study. This suggests that our
assay is independent of the NADH and NADPH concentra-
tion of the sample.
The Free Radical Theory of Ageing postulates that the
progressive loss of function observed in the ageing process is
due to an accumulation of damage to cellular components by
oxidant species [40]. Few studies have thus far examined the
validity of this theory in humans, and this is largely due to the
lack of robust assays suitable for high-throughput analysis.
The oxidising capacity of plasma, as measured by our modi-
fied AOPP assay, increased with age in the sample population
of 90 subjects, supporting previous findings of an accumu-
lation of oxidative stress in human ageing by other groups
[41–47]. It should be noted, however, that the prevalence of
hypertension increases with advancing age, and the cause-
effect relationship of AOPP in ageing and hypertension has
not yet been established. Further studies would be required
to determine whether AOPP accumulate with age and pre-
dispose to hypertension, or whether AOPP are markers of
hypertension that becomes more likely in older individuals.
AOPP have been widely accepted into the field of oxida-
tive stress research, as a marker of plasma protein oxidative
damage [8–10, 12, 15, 17, 18, 22, 23, 31, 35, 38, 41, 44, 48–51].
However, on thorough study of the literature, it is apparent
that two discrete versions of the AOPP assay exist which
both, at first sight, resemble an assay tomeasure chloramines,
in which the oxidation of iodide (I−) to triiodide (I
3
−) by
phagocyte-derived chloramines is measured [52]. It is clear
that the analytes measured in the two versions of the AOPP
assay are different, but this discrepancy has not previously
been pointed out.
In one version of the AOPP assay, optical density of
the plasma sample at 340 nm is simply measured in the
presence of acid [4, 5, 36, 48, 49] and is apparently based
on the rationale that oxidatively modified proteins absorb
light at 340 nm to a greater extent than native proteins under
acidic conditions [53]. The relevance of using chloramine
T as a standard [2, 36, 49, 50] is not made clear. In this
version of the assay, the measured AOPP are reported to
be carried largely by oxidised albumin and are made up of
numerous chromophores including dityrosine, pentosidine,
and protein carbonyls [53], but AOPP themselves have no
measured oxidising capacity. The second version of the
method examines the iodide oxidising capacity of plasma,
and this is the principle of the assay developed in the present
study [8–10, 12, 17]. Using this version of the assay, AOPP are
reported to comprise oxidised fibrinogen [21, 30].
AOPP have previously been reported to be elevated in
both Type 1 and Type 2 diabetic patients compared with
healthy controls, but some studies were carried out using
the AOPP protocol in which KI is only added to the
standards [38] and others examining plasma iodide oxidising
capacity [8–10, 12, 17]. In yet further studies on AOPP in
diabetes, it was unclear which protocol was followed [15, 18,
51]. Differences in methodology may partially explain the
discrepancy in AOPP values published in previous studies of
oxidative stress. Reported AOPP concentrations in control
groups vary greatly between studies, with concentrations
ranging from 0.11 ± 0.05 [17] to 259 ± 75 𝜇M [12] chloramine
T equivalents, and on examination of the two versions of
the assay it appears that the two published AOPP methods
measure different analytes. Additionally, failure to correct
for precipitation or inherent triglyceride concentrations may
influence AOPP concentrations determined during these
studies. The availability of a robust assay of AOPPTIOC
will facilitate further studies to characterise the components
responsible for plasma TIOC activity.
In summary, we have identified inconsistencies in the
published protocols by which AOPP is measured, which have
not previously been highlighted. One such method is con-
founded by precipitation which causes variability between
replicates and overestimation of AOPP concentrations. We
have developed a modified version of this method (named
AOPPTIOC) which eliminates the effect of precipitation and
has been shown to increase with age in human plasma and
is significantly associated with hypertension, suggesting that
it may be a marker of endothelial dysfunction. We strongly
urge other researchers wishing to publish AOPP data to be
particularly careful in the description of their methodology,
especially with regard to whether or not I− is added to plasma
samples as well as to standards.
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